Significance of CA125 Monitoring during Maintenance Treatment with Poly(ADP-Ribose) Polymerase Inhibitor in Ovarian Cancer after First-Line Chemotherapy: Multicenter, Observational Study
GCIG biochemical progression criteria during PARPis maintenance treatment after first-line chemotherapy missed 46.3% of progressing patients. A new criterion-CA125 ≥3× nadir-improves sensitivity and NPV, while maintaining high specificity, offering a simple and practical approach for clinical implementation.
Authors
- Aleksandra Zielińska (ORCID: https://orcid.org/0000-0002-8325-0261)
- Bartosz Szymanowski (ORCID: https://orcid.org/0000-0002-4135-7079)
- Renata Duchnowska (ORCID: https://orcid.org/0000-0002-9272-3462)
- Mariusz Bidziński (ORCID: https://orcid.org/0000-0003-4767-6369)
- Wojciech Michalski (ORCID: https://orcid.org/0000-0003-4366-6104)
- Nadia Sawicka
- Paweł Derlatka (ORCID: https://orcid.org/0000-0001-9406-6868)
- Szymon Piątek (ORCID: https://orcid.org/0000-0002-7798-3549)
- Anna Dańska-Bidzińska (ORCID: https://orcid.org/0000-0001-9518-5623)
- Aleksander Gorzeń
Institutions
- Medical University of Warsaw (PL)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-01-01
- DOI
- https://doi.org/10.32604/or.2025.068609
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00